LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 57

Search options

  1. Article ; Online: CML stem cells: evasion for better invasion.

    Nicolini, Franck Emmanuel

    Blood

    2017  Volume 129, Issue 2, Page(s) 141–142

    MeSH term(s) Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Neoplastic Stem Cells ; Stem Cells
    Chemical Substances Imatinib Mesylate (8A1O1M485B)
    Language English
    Publishing date 2017-01-11
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2016-11-750554
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Recommandations 2022 du groupe Fi-LMC pour la gestion du risque d’événements cardiovasculaires sous ponatinib dans la leucémie myéloïde chronique.

    Réa, Delphine / Messas, Emmanuel / Mirault, Tristan / Nicolini, Franck Emmanuel

    Bulletin du cancer

    2022  Volume 109, Issue 7-8, Page(s) 862–872

    Abstract: Tyrosine kinase inhibitors targeting the BCR-ABL1 oncoprotein represent an outstanding progress in chronic myeloid leukemia and long-term progression-free survival has become a reality for a majority of patients. However, tyrosine kinase inhibitors may ... ...

    Title translation French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia.
    Abstract Tyrosine kinase inhibitors targeting the BCR-ABL1 oncoprotein represent an outstanding progress in chronic myeloid leukemia and long-term progression-free survival has become a reality for a majority of patients. However, tyrosine kinase inhibitors may at best chronicize rather than cure the disease thus current recommendation is to pursue treatment indefinitely. As a consequence, high quality treatment and care must integrate optimal disease control and treatment tolerability. Tyrosine kinase inhibitors have an overall favorable safety profile in clinical practice since most adverse events are mild to moderate in intensity. However, recent evidence has emerged that new generation tyrosine kinase inhibitors may sometimes damage vital organs and if not adequately managed, morbidity and mortality may increase. The 3rd generation tyrosine kinase inhibitor ponatinib is licensed for the treatment of chronic, accelerated or blast phase chronic myeloid leukaemia patients who are resistant to dasatinib or nilotinib; intolerant of dasatinib or nilotinib and for whom further treatment with imatinib is not clinically appropriate; or who express the T315I mutation. Ponatinib represents an important therapeutic option but it is associated with an increased risk of cardiovascular events. The purpose of this article by the France Intergroupe des Leucémies Myéloïdes Chroniques is to provide an overview of ponatinib efficacy and cardiovascular safety profile and to propose practical recommendations with the goal to minimize the risk and severity of cardiovascular events in ponatinib-treated patients.
    MeSH term(s) Antineoplastic Agents/adverse effects ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/prevention & control ; Dasatinib ; Drug Resistance, Neoplasm ; Fusion Proteins, bcr-abl ; Humans ; Imidazoles ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Protein Kinase Inhibitors/adverse effects ; Pyridazines
    Chemical Substances Antineoplastic Agents ; Imidazoles ; Protein Kinase Inhibitors ; Pyridazines ; ponatinib (4340891KFS) ; Fusion Proteins, bcr-abl (EC 2.7.10.2) ; Dasatinib (RBZ1571X5H)
    Language French
    Publishing date 2022-06-17
    Publishing country France
    Document type Practice Guideline ; Journal Article
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2022.04.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.15: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia.

    Huguet, Françoise / Réa, Delphine / Cayssials, Emilie / Etienne, Gabriel / Nicolini, Franck-Emmanuel

    Expert review of hematology

    2023  Volume 16, Issue 9, Page(s) 633–639

    Abstract: Introduction: Ponatinib exhibits a high inhibition potency on wild-type and most mutated forms of the : Areas covered: Based on pharmacological findings and international guidelines on chronic myeloid leukemia and cardiovascular risk management, as ... ...

    Abstract Introduction: Ponatinib exhibits a high inhibition potency on wild-type and most mutated forms of the
    Areas covered: Based on pharmacological findings and international guidelines on chronic myeloid leukemia and cardiovascular risk management, as well as on the most recent data collected in real-life studies and in a randomized phase II trial, we propose a decision-tree of dose selection of the drug.
    Expert opinion: We distinguish (1) highly resistant patients according to poor previous response to second generation tyrosine kinase inhibitors (complete hematologic response or less) or to mutational status (T315I, E255V, alone or within compound mutations), requiring a starting daily dose of 45 mg, reduced to 15 or 30 mg according to the patient's profile, preferentially upon major molecular achievement (3-log reduction or MR3,
    MeSH term(s) Humans ; Antineoplastic Agents/adverse effects ; Drug Resistance, Neoplasm/genetics ; Fusion Proteins, bcr-abl/genetics ; Protein Kinase Inhibitors/adverse effects ; Leukemia, Myeloid, Chronic-Phase/drug therapy ; Leukemia, Myeloid, Chronic-Phase/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Pyridazines/adverse effects
    Chemical Substances Antineoplastic Agents ; ponatinib (4340891KFS) ; Fusion Proteins, bcr-abl (EC 2.7.10.2) ; Protein Kinase Inhibitors ; Pyridazines
    Language English
    Publishing date 2023-07-27
    Publishing country England
    Document type Clinical Trial, Phase II ; Randomized Controlled Trial ; Journal Article
    ZDB-ID 2516804-6
    ISSN 1747-4094 ; 1747-4086
    ISSN (online) 1747-4094
    ISSN 1747-4086
    DOI 10.1080/17474086.2023.2234084
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6943: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation.

    Nicolini, Franck-Emmanuel / Huguet, Françoise / Huynh, Lynn / Xu, Churong / Bouvier, Christophe / Yocolly, Aurore / Etienne, Gabriel

    Cancers

    2023  Volume 15, Issue 16

    Abstract: This retrospective chart review study investigated the clinical burden of adult patients with chronic-phase chronic myeloid leukemia (CP-CML) treated at three centers in France (2006-2021) who failed on two or more tyrosine kinase inhibitors (TKIs; third- ...

    Abstract This retrospective chart review study investigated the clinical burden of adult patients with chronic-phase chronic myeloid leukemia (CP-CML) treated at three centers in France (2006-2021) who failed on two or more tyrosine kinase inhibitors (TKIs; third-line [3L]+ cohort) or harbored the
    Language English
    Publishing date 2023-08-18
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15164161
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: T315I+ tyrosine-kinase independent CML cells resistance.

    Nicolini, Franck Emmanuel / Grockowiak, Elodie / Maguer-Satta, Véronique

    Oncotarget

    2017  Volume 8, Issue 27, Page(s) 43600–43601

    Language English
    Publishing date 2017-06-14
    Publishing country United States
    Document type News
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.18573
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Optimisation du bosutinib dans la leucémie myéloïde chronique : recommandations du Fi-LMC (France Intergroupe des leucémies myéloïdes chroniques).

    Rea, Delphine / Cayssials, Emilie / Charbonnier, Aude / Coiteux, Valérie / Etienne, Gabriel / Goldwirt, Lauriane / Guerci-Bresler, Agnès / Huguet, Françoise / Legros, Laurence / Roy, Lydia / Nicolini, Franck Emmanuel

    Bulletin du cancer

    2023  Volume 111, Issue 1, Page(s) 87–96

    Abstract: The treatment of chronic myeloid leukemia relies on orally available tyrosine kinase inhibitors targeting the BCR::ABL1 oncoprotein. Bosutinib is a second generation adenosine triphosphate-competitive inhibitor approved for use in frontline adult chronic ...

    Title translation Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group).
    Abstract The treatment of chronic myeloid leukemia relies on orally available tyrosine kinase inhibitors targeting the BCR::ABL1 oncoprotein. Bosutinib is a second generation adenosine triphosphate-competitive inhibitor approved for use in frontline adult chronic phase-chronic myeloid leukemia and all phases-chronic myeloid leukemia in the second line setting or beyond. Its efficacy was demonstrated in several pivotal clinical trials at 400mg once daily in the first line context and at 500mg once daily beyond first line. Bosutinib-related adverse events frequently occur early after treatment initiation and include gastro-intestinal symptoms and cytolytic hepatitis. These drug-related adverse events must be properly managed in order to preserve safety, efficacy and treatment acceptability. The French chronic myeloid leukemia study group gathered a panel of experts in hematology, pharmacology and hepatology in order to elaborate practical recommendations on the management of bosutinib treatment. These recommendations aim at optimizing the short and long-term tolerance and benefit/risk balance of bosutinib, mainly focusing at gastro-intestinal and liver toxicities.
    MeSH term(s) Adult ; Humans ; Antineoplastic Agents/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Aniline Compounds/adverse effects ; Nitriles/adverse effects ; Quinolines/adverse effects ; Leukemia, Myeloid, Chronic-Phase/drug therapy
    Chemical Substances bosutinib (5018V4AEZ0) ; Antineoplastic Agents ; Protein Kinase Inhibitors ; Aniline Compounds ; Nitriles ; Quinolines
    Language French
    Publishing date 2023-12-11
    Publishing country France
    Document type English Abstract ; Journal Article ; Review
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2023.10.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.15: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study.

    Etienne, Gabriel / Rea, Delphine / Coiteux, Valerie / Guerci-Bresler, Agnès / Huguet, Françoise / Legros, Laurence / Rousselot, Philippe / Nicolini, Franck-Emmanuel

    Leukemia research

    2021  Volume 104, Page(s) 106541

    MeSH term(s) Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; France/epidemiology ; Humans ; Imidazoles/administration & dosage ; Imidazoles/adverse effects ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality ; Male ; Middle Aged ; Pyridazines/administration & dosage ; Pyridazines/adverse effects
    Chemical Substances Imidazoles ; Pyridazines ; ponatinib (4340891KFS)
    Language English
    Publishing date 2021-03-02
    Publishing country England
    Document type Clinical Trial, Phase II ; Letter ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2021.106541
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.

    Kockerols, Camille / Valk, Peter J M / Dulucq, Stéphanie / Nicolini, Franck-Emmanuel / Mahon, François-Xavier / Atallah, Ehab / Mauro, Michael J / Radich, Jerald P / Bernardi, Simona / Russo, Domenico / Farina, Mirko / Mori, Silvia / Gambacorti-Passerini, Carlo / Civettini, Ivan / Lu, Liu / Yeung, David / Branford, Susan / Colafigli, Gioia / Breccia, Massimo /
    Hogenbirk, Pauline / van Rosmalen, Joost / Cornelissen, Jan J / Westerweel, Peter E

    American journal of hematology

    2024  

    Language English
    Publishing date 2024-05-20
    Publishing country United States
    Document type Letter
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.27359
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.

    Gambacorti-Passerini, Carlo / Nicolini, Franck Emmanuel / Larson, Richard A / Aroldi, Andrea / Fontana, Diletta / Piazza, Rocco / le Coutre, Philipp / Antolini, Laura / Assouline, Sarit

    American journal of hematology

    2022  Volume 97, Issue 8, Page(s) E296–E298

    MeSH term(s) Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Protein Kinase Inhibitors/adverse effects
    Chemical Substances Protein Kinase Inhibitors
    Language English
    Publishing date 2022-06-09
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26618
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Professeur John M. Goldman 1938-2013.

    Mahon, François-Xavier / Reiffers, Josy / Nicolini, Franck Emmanuel

    Bulletin du cancer

    2014  Volume 101, Issue 3, Page(s) 224

    Title translation Professor John M. Goldman 1938-2013.
    MeSH term(s) Antineoplastic Agents/history ; Benzamides/history ; Hematology/history ; History, 20th Century ; History, 21st Century ; Imatinib Mesylate ; Piperazines/history ; Pyrimidines/history ; United Kingdom
    Chemical Substances Antineoplastic Agents ; Benzamides ; Piperazines ; Pyrimidines ; Imatinib Mesylate (8A1O1M485B)
    Language French
    Publishing date 2014-03
    Publishing country France
    Document type Biography ; Historical Article ; Journal Article ; Portraits
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.15: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top